Magenta Therapeutics, Inc.
MGTA · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.18 | 0.30 |
| FCF Yield | -2,864.16% | -5,460.82% | -23.34% | -16.96% |
| EV / EBITDA | 0.18 | 0.33 | -1.72 | -4.09 |
| Quality | ||||
| ROIC | -28.62% | -56.07% | -38.44% | -48.39% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 0.88 | 0.84 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | -10.87% | 5.63% | -7.08% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 0.35 | 1.76 | 0.74 |
| Interest Coverage | 0.00 | 18.22 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |